Uterine Leiomyosarcoma Has Deregulated Cell Proliferation, but Not Increased Microvessel Density Compared with Uterine Leiomyoma (original) (raw)

Abstract

leiomyoma) and malignant uterine smooth muscle tumors Objective. To investigate the differences of biological aggressive-(leiomyosarcoma). Uterine myoma is usually benign lesions ness in terms of proliferating cell nuclear antigen (PCNA) expreswith less than 5 mitoses per 10 HPFs. In contrast, if รบ10 sion, cell proliferation, and microvessel density between uterine mitoses per 10 HPFs are found, the tumor is considered leiomyosarcoma and leiomyoma. malignant [1]. Uterine sarcomas, as a group, are character-Study design. All patients with uterine leiomyosarcoma undergoized by rapid clinical progression, and they carry a poor ing surgery at National Cheng Kung University Hospital were overall prognosis. It is generally believed that the number eligible. Forty-four patients with uterine myoma were also studied of mitoses per 10 HPFs seems to be the most reliable preas the benign counterpart. The paraffin-embedded slides were dictor of biological behavior. However, the mitotic count is stained with hematoxylin and eosin to confirm the presence of still considered to be a fairly crude index of proliferation, tumor and to quantitate mitoses, PC 10 for measurement of PCNA and suffers from limitations [2]. expression, MIB 1 for measurement of cell proliferation, and factor VIII for quantitation of microvessel density. The immunohisto-Proliferating cell nuclear antigen (PCNA), a 36-kDa nuchemical findings of the slides were correlated with clinocopathoclear protein, is a necessary component of the machinery logic findings of the patients, and the data were analyzed by either that copies DNA so that cell division can take place [3, 4].

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (23)

  1. nuclear antigen (PCNA) immunolocalization in paraffin sections: an giogenesis: An imbalance of positive and negative regulation. Cell 64:327 -336, 1991 index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 162:285 -294, 1990
  2. Brem S, Cotran R, Folkman J: Tumor angiogenesis: A quantitative method for histologic grading. J Natl Cancer Inst 48:347-356, 1972
  3. McCormick D, Hall PA: The complexities of proliferating cell nuclear antigen. Histopathology 21:591-594, 1992
  4. Srivastava A, Laidler P, Davis R, Horgan K, Hughes LE: The prognos- tic significance of tumor vascularity in intermediate-thickness (0.76-
  5. Yu CC, Hall PA, Fletcher CD, Camplejohn RS, Waseem NH, Lane 4.0 mm thick) skin melanoma. Am J Pathol 133:419 -423, 1988
  6. DP, Levison DA: Hamangiopericytomas: The prognostic value of im- 18.
  7. Weidner H, Semple JP, Welch WR, Folkman J: Tumor angiogenesis munohistochemical staining with a monoclonal antibody to proliferat- and metastasis: Correlation in invasive breast carcinoma. N Engl J Med ing cell nuclear antigen (PCNA). Histopathology 19:29-33, 1991 324:1 -8, 1991
  8. Shivji MKK, Kenny MK, Wood RD: Proliferating cell nuclear antigen 19. Bosari S, Lee AKC, DeLellis RA, Wiley BD, Heatley GJ, Silverman is required for DNA excision repair. Cell 69:367 -374, 1992 ML: Microvessel quantitation and prognosis in invasive breast carci-
  9. Harrison RF, Renolds GM, Rowlands DC: Immunohistochemical evi- noma. Hum Pathol 23:755 -761, 1992 dence for the expression of proliferating cell nuclear antigen (PCNA)
  10. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Merino by nonprolifrating hepatocytes adjacent to metastatic tumors and in- MJ: Tumor angiogenesis in advanced ovarian carcinoma. Am J Pathol flammatory conditions. J Pathol 171:115 -122, 1993 147:33 -41, 1995
  11. Hall PA, Coates PJ, Goodllad RA, Hart IR, Lane DP: Proliferating cell 21. Garzetti GG, Ciavattini A, Goteri G, De Nictolis M, Stramazzotti D, nuclear antigen expression in non-cycling cells may be induced by Lucarini G: Ki-67 antigen immunostaining (MIB 1 monoclonal anti- growth factors in vivo. Br J Cancer 70:244-247, 1994 body) in serous ovarian tumors: Index of proliferative activity with
  12. Gerdes J, Schwab U, Lemke H, Stein H: Production of a mouse mono- prognostic significance. Gynecol Oncol 56:169-174, 1995
  13. clonal antibody reactive with a human nuclear antigen associated with 22. Huang SC, Yu CH, Huang RT, Hsu KF, Tsai YC, Chou CY: Intratu- cell proliferation. Int J Cancer 31:13-20, 1983 moral blood flow in uterine myoma correlated with a lower tumor size
  14. Key G, Becker MHG, Baron B, Duchrow M, Schluter C, Flad HD, and volume, but not correlated with cell proliferation or angiogenesis.
  15. Gerdes J: New Ki-67 equivalent murine monoclonal antibodies (MIB1- Obstet Gynecol 87:1019-1024, 1996
  16. generated against becterially expressed parts of Ki-67 cDNA con- 23.
  17. Lee WY, Tzeng CC, Chou CY: Uterine Leiomyosarcoma coexistent taining three 62 base pair repetitive elements encoding for the Ki-67 with cellular and atypical leiomyomata in a young woman during the epitope. Lab Invest 68:629-636, 1993 treatment with luteinizing hormone-releasing hormone agonist. Gyne- 13.
  18. Folkman J, Watson K, Ingber D, Hanahan D: Induction of angiogenesis col Oncol 52:74-79, 1994
  19. during the transition from hyperplasia to neoplasia. Nature 339:58-61, 24. Celis JE, Madsen P: Increased nuclear cyclin/PCNA antigen staining 1989 of non S-phase transformed human amnion cells engaged in nucleiotide
  20. Paweletz N, Knierim M: Tumor-related angiogenesis. Crit Rev Oncol excision DNA repair. FEBS Lett 209:277 -283, 1986
  21. Hematol 9:197-242, 1989
  22. Ribitta D, Vacca A, Roncali L, Dammacco F: Angiogenesis under normal and pathological conditions. Haematologica 76:311-320, 1991.
  23. Liotta LA, Steeg PS, Steler-Stevenson WJ: Cancer metastasis and an-